An open-label study on ulotaront's effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I.

Diabetes Obes Metab · 2026 · PMC12673454 · PMID 41126393

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The insulin response after a solid meal was nominally significant, suggesting that semi‐chronic twice‐a‐day dosing of ulotaront might improve insulin dynamics in schizophrenia patients at high diabetes risk.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.